The p38 MAPK family consists of highly conserved proline-directed serine-threonine protein kinases that are activated in response to a number many growth factors, cytokines, and chemotactic substances, such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), PDGF, TNF, interleukins, lipopolysaccharide (LPS) and formyl-methionyl-leucyl-phenylalanine (fMLP).It is well known that p38 plays a role in cell differentiation, cardiomyocyte hypertrophy, apoptosis, and inflammation.
The four proteins that make up the p38 MAPK family are p38 (encoded by the gene Mapk14), p38 (Mapk11), p38 (Mapk12), and p38 (Mapk13). Their coding genes appear to be differentially expressed and have a distinct tissue distribution, with Mapk14 being the most highly expressed. MKK6, MKK3, and MKK4 are three MAP2Ks that p38 MAPKs are a substrate for. Depending on the stimulus and the cell type, each of these MAP2Ks plays a different role in the activation of p38 MAPKs. ASK1, DLK1, TAK1, TAO1, TAO2, TPL2, MLK3, MEKK3, MEKK4, and ZAK1 are the MAP3Ks that activate p38 MAPKs.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V2950 | SB-242235 | 193746-75-7 | SB-242235 is a potent and selective p38 MAP kinase inhibitor with IC50 of 1.0 uM and has the potential for treatment of cytokine-mediated diseases like autoimmune or inflammatory diseases. |
|
V0478 | SB202190 (FHPI) | 152121-30-7 | SB-202190 (known also as SB202190; FHPI) is a novel, highly selective, potent and cell-permeable inhibitor of p38 MAPK with potential antiseptic activity. |
|
V0483 | SB239063 | 193551-21-2 | SB239063 (SB-239063) is a novel, highly potent, orally bioactive and selective p38 MAPKα/β inhibitor with potential anti-inflammatory activity. |
|
V3013 | SD-06 | 271576-80-8 | SD-06 is an inhibitor of p38 alpha MAP kinase which inhibits p38α with an IC50 value of 170 nM and inhibits LPS-stimulated TNF-release in rats with 83% inhibition at an oral dose of 1mg/kg. |
|
V0486 | Skepinone-L (CBS3830) | 1221485-83-1 | Skepinone-L (CBS-3830; CBS3830)is a novel, potent, selective and ATP-competitive inhibitor p38α-MAPK with potential anti-inflammatory activity. |
|
V3025 | SKF-86002 | 72873-74-6 | SKF-86002 is a novel and potent inhibitor of the p38 MAP kinase with IC50 of 0.5-1 uM; it inhibits LPS-induced IL-1 and TNF-α production in human monocytes with IC50 of 1 μM. |
|
V74112 | SKF-86002 dihydrochloride | 116339-68-5 | SKF-86002 di-HCl is an orally bioactive p38 MAPK inhibitor (antagonist) with anti-inflammatory and anti-arthritic activities and may be utilized in pain relief research. |
|
V104750 | SPA0355 | 1251839-15-2 | SPA0355 is a thiourea derivative with antioxidant and anti-inflammatory activities. |
|
V104177 | SR-302 | 2771319-74-3 | SR-302 is a potent and selective DDR/p38 inhibitor with IC50 values of 0.125, 0.023, and 0.018 μM for p38α, DDR1, and DDR2, respectively. |
|
V51550 | SX-011 | 309913-42-6 | p38 inhibitor |
|
V15645 | TA-02 | 1784751-19-4 | TA-02 is an analog of SB 203580 and an inhibitor (blocker/antagonist) of p38 MAPK with IC50 of 20 nM. |
|
V0487 | TAK-715 | 303162-79-0 | TAK-715 is a novel, potent and selective p38 MAPK (p38 mitogen-activated protein) inhibitorwith potential anti-inflammatory activity. |
|
V87101 | TIC10g | 754998-88-4 | TIC10g is a dual inhibitor of Toll-like receptors 7 and 9 (TLR7 and TLR9), which inhibits TLR7- and TLR9-mediated TNF-α release in mouse macrophages (IC50: 14.5 μM and 6.5 μM, respectively) and human B lymphocytes (IC50: 7.69 μM and 11.5 μM, respectively). |
|
V74125 | TLR4/NF-κB/MAPK-IN-1 | 2767567-26-8 | TLR4/NF-κB/MAPK-IN-1 is a new anti-neuroinflammatory agent by inhibiting the TLR4/NF-κB/MAPK pathway. |
|
V74113 | Torilin | 13018-10-5 | Torilin is a sesquiterpene with antibacterial, anticancer and anti-inflammatory activities. |
|
V105606 | Tropisetron-d5 | 1220284-86-5 | Tropisetron-d5 (SDZ-ICS-930-d5 (free base)) is a deuterated tropisetron. |
|
V0480 | VX-702 | 745833-23-2 | VX-702 is a novel, highly potent,orally bioavailableand selective inhibitor of p38α MAPK with potential anti-inflammatory activity. |
|
V9029 | Metformin | 657-24-9 | Metformin (La-6023; SMP-862; ADX-155; EFB-0027; EX404; La6023; SMP862; Fortamet) is an approved hypoglycemic drug for the treatment of type 2 diabetes (non-insulin-dependent diabetes mellitus). |
|
V30970 | Talmapimod (SCIO 469) | 309913-83-5 | Talmapimod, formerly known as SCIO-469, is a novel, orally bioavailable, and selective p38 mitogen-activated protein kinase (MAPK) inhibitor (IC50 = 9 nM) with potential immunomodulating, anti-inflammatory, and antineoplastic activities. |
|
V0477 | BIRB 796 (Doramapimod) | 285983-48-4 | BIRB 796 (also known as doramapimod) is a novel, orally bioactive, and highly potentpan-p38 MAPK inhibitor with potential anti-inflammatory activity. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
